Psilocybe Mushrooms, Demystifying Magic
A tour de force of psilocybe mushrooms from historical use, legal status, growth cycles, understanding chemical makeup, and how psilocybin affects the brain and body.
Bruce Linton: Still Deal-Making and Shaping the Cannabis Landscape
Bruce Linton may forever be known for jumpstarting the Canadian cannabis industry as CEO of Canopy Growth. Or that may simply be known as his first home run. His next opportunity, Gage Cannabis, led the charge into the slowly loosening U.S. market via Michigan, with 19 “Class C” cultivation licenses, 15 dispensaries, and three processing licenses. And now, Gage has become a bigger player with the company’s all-stock $545 million purchase by TerrAscend. Bruce has graced us with his presence before, each time with some new venture percolating. In this keynote address, expect some hints of things to come.
Interviewer – Samantha Roman
What It Takes To Go Micro
There are big growers and there are micro-cultivators. And as strange as it may seem, there are more hoops to jump through and licenses to pay for if you decide to grow the cannabis equivalent of a craft beer. With processor licenses, sales licenses, nursery licenses and harvest limits, experts say a start-up could cost anywhere from $250k to $2 million. And yet, as consumer connoisseurship grows, and the willingness to pay for quality follows, micro-cultivators may be ideally suited to experiment with and grow higher-quality strains. This panel will examine the potential profit of limited-edition cannabis growing versus the cost.
Moderator – Dr. Av Singh
International Emerging Cannabis Markets
Truly a global phenomenon, cannabis is finding devotees in all its incarnations, from recreational to hemp to medicinal (Israel, for example, recently passed Germany as the largest importer of medicinal flowers). There is practically no place in the world where demand does not tempt investors. At the same time, there are many countries that still outlaw the drug. And COVID-19 has created its own foreign investment barriers, from restrictions on retail and travel to supply chain disruptions. Various market research studies have tried to make sense out of the emerging international market. This session will tell you what we know, what we don’t know, and what the profit potential is from Africa to Asia to Europe to South America.
Moderator – Matt Lamers
State of the Industry: Are We Ready For Good News?
In a pandemic-stricken global economy, there is every reason to expect the worst. But despite what many consider high and/or unfair taxes, regulatory handcuffs and crippled supply chains, the durability of the cannabis industry has surprised many. In a research report from Prospiant and Cannabis Business Times, 31% of participants reported increased revenues in 2020 and 73% planned to imminently add cultivation space (indoor, outdoor or greenhouse). Is it overly optimistic to expect these trends to continue, or does this suggest better things to come? We’ll assess our industry’s strengths and its ability to endure.
Moderator – Terry Roycroft
An Interview with Michael Patterson NHA, OTR/L, CEAS- CEO, US Cannabis Pharmaceutical Research and Development
Cannabis Industry Veteran, USA healthcare industry expert, Social Media Influencer, and Podcast host Michael Patterson sits down with Samantha Roman to discuss current industry trends, International trade, ancillary businesses opportunities related to cannabis, the cannabis global value chain, cannabis education, and much more!
Michael Patterson is the CEO of US Cannabis Pharmaceutical Research and Development, which focuses on moving society forward through legalized cannabis. US Cannabis develops the legal cannabis/hemp/cbd industry across multiple platforms (cultivation, processing, dispensing, trade, education, regulation/law, licensing, payments, compliance). Mr. Patterson is also President of MGMC Pharma Group (International Pharmaceutical company focusing on vaccine development and cannabis products), Advisory Board member for Akers Bio (NASDAQ listed company), Editorial Board member for AJEM-American Journal of Endocannabinoid Medicine (world’s first peer reviewed, printed journal dedicated to the study of the endocannabinoid science), Advisory Board member for ICS- Integrated Compliance Solutions (largest merchant processor for THC and hemp/cbd related businesses in the USA), and Podcast host of “The Cannabis Report with Michael Patterson”.
Moderator – Samantha Roman
Opening Remarks
Psychedelic Outlook 2021: How Far Can This Industry Go?
Industry analysts are bullish about the financial potential of the psychedelic drug market, predicting North American sales of almost $7 billion by 2027. A continuing search for new and effective treatments for burgeoning mental illnesses fuels the confidence. On the other hand, new medicinal drugs can face more regulatory roadblocks than recreational ones. This panel, representing some of the most active companies in psychedelic research and development, will come up with a realistic timetable for the full greenlight for licensed psychoactive healing.
Moderator – Katie Pringle
Honouring Indigenous Roots
Scientists studying the clinical applications of psychedelics inevitably find their way to ayahuasca shamanism and the role of natural mind-altering substances in Indigenous spirituality and religious practice. In a field of study where science and religion can truly co-exist, researchers and non-Indigenous people must be mindful of honouring the traditions of sacred plants as they attempt to build a bridge between Native cultures and the efficacy of their medicine. This session will consider the traditional use of psychedelics and the reciprocity that must come with adapting it.
Recent Comments